Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hypercalcemia associated with chronic lymphocytic leukemia.

R H Laugen, R M Carey, M R Wills

    Archives of Internal Medicine
    |November 1, 1979
    PubMed
    Summary

    Hypercalcemia in chronic lymphocytic leukemia (CLL) is linked to increased tumor burden. Chemotherapy resolved hypercalcemia, which returned upon relapse, suggesting CLL cells produced a parathyroid hormone-like substance.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A hospital outbreak of an NDM-producing ST167 Escherichia coli with a possible link to a toilet.

    The Journal of hospital infection·2021
    Same author

    Advances in the treatment of cytomegalovirus.

    British medical bulletin·2019
    Same author

    A Coagulation Defect in Amyloidosis.

    The Medical journal of the South-West·2017
    Same author

    LPS promotes a monocyte phenotype permissive for human cytomegalovirus immediate-early gene expression upon infection but not reactivation from latency.

    Scientific reports·2017
    Same author

    Transient activation of human cytomegalovirus lytic gene expression during latency allows cytotoxic T cell killing of latently infected cells.

    Scientific reports·2016
    Same author

    Diverse specificities, phenotypes, and antiviral activities of cytomegalovirus-specific CD8+ T cells.

    Journal of virology·2014

    Area of Science:

    • Hematology
    • Oncology
    • Endocrinology

    Background:

    • Chronic lymphocytic leukemia (CLL) is a hematologic malignancy characterized by the proliferation of mature B lymphocytes.
    • Hypercalcemia is a potential complication in various cancers, but its direct association with CLL requires further elucidation.
    • Understanding the mechanisms of cancer-related hypercalcemia is crucial for effective patient management.

    Observation:

    • A case study details a patient with CLL experiencing hypercalcemia coinciding with elevated lymphocyte counts and tumor mass expansion.
    • The patient's hypercalcemia resolved following chemotherapy, which reduced white blood cell (WBC) count and tumor burden.
    • Hypercalcemia recurred upon relapse of the leukemic process, indicating a direct link to the disease activity.

    Findings:

    Related Experiment Videos

    • Serum calcium levels were elevated in conjunction with increased peripheral lymphocyte counts and overall tumor burden in the CLL patient.
    • Treatment-induced reduction in tumor burden and WBC count led to the amelioration of hypercalcemia.
    • Recurrence of hypercalcemia correlated with leukemic relapse, reinforcing the association.
    • Inappropriately elevated serum immunoreactive parathyroid hormone (iPTH) levels were observed relative to the degree of hypercalcemia.
    • The findings suggest CLL cells may secrete a parathyroid hormone-like polypeptide, causing hypercalcemia.

    Implications:

    • This case suggests that hypercalcemia in CLL can be a direct paraneoplastic manifestation, potentially mediated by CLL cell-secreted factors.
    • The elevated iPTH levels point towards a specific mechanism, possibly involving a parathyroid hormone-like polypeptide, rather than solely osteoclast-activating substances or prostaglandins.
    • Effective management of hypercalcemia in CLL may involve addressing the underlying leukemic process and tumor burden.
    • Further research into the specific mediators secreted by CLL cells is warranted to confirm this mechanism and explore targeted therapies.